All In Biotech

Drug Trial Radar · NCT02207634

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

Last checked: Nov 20, 2026Latest source record: Jan 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,974 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,974

Actual

Start

Sep 10, 2014

Primary completion

Nov 11, 2016

Study completion Nov 11, 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.

Conditions

  • Dyslipidemia

Interventions

  • EvolocumabBiological

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

  • PlaceboDrug

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

  • Background Statin TherapyDrug

    Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z ScoreTime frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).

Locations

416 sites in 30 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Alhambra, California

  • Research Site

    Banning, California

  • Research Site

    Harbor City, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Oceanside, California

  • Research Site

    Oxnard, California

  • Research Site

    Palm Springs, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Pedro, California

  • Research Site

    Tarzana, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Crystal River, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Deerfield Beach, Florida

  • Research Site

    Fleming Island, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Ponte Vedra, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Atlanta, Georgia

Showing 40 of 416 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.